Positive Magnetic Resonance Imaging Evidence of Transient Global Amnesia Following the Use of Sildenafil.

abstract：:Neuroleptic-induced tardive dyskinesia (TD) that persists for 1 year or more following withdrawal of neuroleptics is usually said to be permanent. Early spontaneous remissions have been well described but most such remissions occurred within the first few months following neuroleptic withdrawal, and no published studi...

journal_title：Clinical neuropharmacology

authors： Klawans HL,Tanner CM,Barr A

更新日期：1984-01-01 00:00:00

abstract：:We describe a 78-year-old gentleman who, following bilateral above-knee amputations, developed symptoms of restless legs syndrome in the absent portions of his lower extremities. These symptoms improved with dopamine agonist therapy. In addition, he later developed parkinsonism with prominent rest tremor on metoclopra...

journal_title：Clinical neuropharmacology

authors： Hanna PA,Kumar S,Walters AS

更新日期：2004-03-01 00:00:00

abstract：:Levodopa is the most effective drug for symptomatic control of Parkinson syndrome (PS). We report a 22-year clinicopathological study of 59 PS cases. Of the entire group, 37 (63%) had an adequate trial on levodopa. Some improvement was noted on that drug in 24 (65%) cases. Improvement was seen in 94% of idiopathic Par...

journal_title：Clinical neuropharmacology

authors： Rajput AH,Rozdilsky B,Rajput A,Ang L

更新日期：1990-12-01 00:00:00

abstract：:We studied the effectiveness of OR-611 and OR-462, two novel inhibitors of the enzyme catechol-O-methyltransferase (COMT), on 3-O-methyldopa (OMD) formation in cynomolgus monkeys following intravenous levodopa administration. OR-611 dose-dependently reduced the area under the OMD concentration-vs-time curve, reduced m...

journal_title：Clinical neuropharmacology

authors： Cedarbaum JM,Leger G,Guttman M

更新日期：1991-08-01 00:00:00

abstract：:Four to 10% of patients with Parkinson disease and chronically treated with levodopa undergo an addictionlike behavioral disturbance named dopamine dysregulation syndrome (DDS). This article suggests that patients with Parkinson disease could be especially prone to develop DDS due to the dopamine deficiency and the "p...

journal_title：Clinical neuropharmacology

authors： Linazasoro G

更新日期：2009-01-01 00:00:00

abstract：:Heart rate variability (HRV) reflects the cardiac autonomic regulation, and reduced HRV is considered a pathophysiological link between depression and cardiovascular mortality. So far, there is only limited information on the effects of venlafaxine and mirtazapine on HRV.We studied 28 nondepressed controls and 41 mode...

journal_title：Clinical neuropharmacology

authors： Terhardt J,Lederbogen F,Feuerhack A,Hamann-Weber B,Gilles M,Schilling C,Lecei O,Deuschle M

更新日期：2013-11-01 00:00:00

abstract：:Hypereosinophilia is asymptomatic but can induce organ damage, which may cause neurological system abnormalities. We recently encountered a 29-year-old woman with depressive episodes who had eosinophilia as well as hyperventilation attacks, tremor, insomnia, and arthralgia of extremities after receiving paroxetine tre...

journal_title：Clinical neuropharmacology

authors： Yasui-Furukori N,Sato Y,Kato H,Kaneko S

更新日期：2012-01-01 00:00:00

abstract：OBJECTIVES:To assess quantitatively the influence of rotigotine transdermal patch on daytime sleepiness, the most common adverse event by non-ergot dopamine agonists (DAs), in Parkinson disease (PD) patients. METHODS:An open-label study enrolled PD patients with unsatisfactory control of motor symptoms. Treatment with...

journal_title：Clinical neuropharmacology

authors： Ohta K,Osada T

更新日期：2015-11-01 00:00:00

abstract：:Calcitonin gene-related peptide (CGRP) is a signaling neuropeptide released from activated trigeminal sensory afferents in headache and facial pain disorders. There are a handful of CGRP-targeted therapies currently in phase 3 studies for migraine acute treatment or prevention. Currently, 4 monoclonal antibodies targe...

journal_title：Clinical neuropharmacology

authors： Schuster NM,Rapoport AM

更新日期：2017-07-01 00:00:00

abstract：:Clozapine often causes low-grade fever and less frequently spiking fever. We describe three cases of spiking fever that occurred in the first 3 weeks of clozapine therapy. A new set of side effects of clozapine is identified, which includes spiking fever, respiratory and gastrointestinal symptoms, and neutrophilia. Po...

journal_title：Clinical neuropharmacology

authors： Trémeau F,Clark SC,Printz D,Kegeles LS,Malaspina D

更新日期：1997-04-01 00:00:00

abstract：OBJECTIVES:The high incidence of fibrotic cardiac valvulopathies reported in association with the 8beta-ergoline dopamine (DA) agonist, pergolide, and also case reports for cabergoline and bromocriptine have made it necessary to review the theoretical basis and actual findings in the case of another DA agonist, the 8al...

journal_title：Clinical neuropharmacology

authors： Hofmann C,Penner U,Dorow R,Pertz HH,Jähnichen S,Horowski R,Latté KP,Palla D,Schurad B

更新日期：2006-03-01 00:00:00

abstract：:Sarcosinemia is a relatively rare autosomal recessive disorder that has a varied phenotypic presentation; rarely, it is associated with neurodevelopmental and neurological abnormalities. Sarcosine is a key intermediate in 1-carbon metabolism, and its elevation in blood and urine could reflect a deficient pool size of ...

journal_title：Clinical neuropharmacology

authors： Deutsch SI,Rosse RB,Long KD,Gaskins B,Mastropaolo J

更新日期：2006-11-01 00:00:00

abstract：BACKGROUND:Serotonin syndrome is a potentially fatal complication that usually occurs in the combination use of several serotonergic agents. We presented a patient with major depressive disorder under the treatment of bupropion, trazodone, and quetiapine. Serotonin syndrome developed soon after she received the first s...

journal_title：Clinical neuropharmacology

authors： Cheng YC,Liang CM,Liu HC

更新日期：2015-05-01 00:00:00

abstract：:Monoamine oxidase (MAO) inhibitors (MAOIs) provide effective alternative therapy for those patients with major depression who do not respond to tricyclic antidepressants or such related compounds as the selective serotonin reuptake inhibitors. This article reviews studies on the efficacy of both the classical MAOIs an...

journal_title：Clinical neuropharmacology

authors： Nolen WA,Hoencamp E,Bouvy PF,Haffmans PM

更新日期：1993-01-01 00:00:00

abstract：:Fluctuations in motor performance are the major problems in chronic management of Parkinson's disease. Most of these fluctuations reflect the decline of levodopa availability. As a consequence, levodopa dosage might be increased and the interdose interval progressively shortened. The postsynaptic dopamine receptors at...

journal_title：Clinical neuropharmacology

authors： Stocchi F,Patsalos PN,Berardelli A,Barbato L,Bonamartini A,Manfredi M,Ruggieri S

更新日期：1994-01-01 00:00:00

abstract：:Dehydroepiandrosterone (DHEA) is an important neurosteroid and has demonstrated efficacy in the improvement of mood and energy. The authors previously reported the efficacy of DHEA augmentation in the management of negative, depressive, and anxiety symptoms of schizophrenia. To characterize further the effects of DHEA...

journal_title：Clinical neuropharmacology

authors： Strous RD,Maayan R,Kotler M,Weizman A

更新日期：2005-11-01 00:00:00

abstract：:Antiepileptic drugs (AEDs) suppress seizures by selectively modifying the excitability of neurons and blocking seizure firing with minimal disturbance of nonepileptic activity. All AEDs have been shown to work by at least one of 3 main mechanisms of action: through modulation of voltage-gated ion channels, enhancement...

journal_title：Clinical neuropharmacology

authors： Biton V

更新日期：2007-07-01 00:00:00

abstract：:A matter of debate is the impact of levodopa (LD) application in patients with Parkinson disease (PD) on altered force development and coordination, which are also influenced by the strength of muscles used. The objectives were to compare the motor response, the development of grip strength, and the pharmacokinetic be...

journal_title：Clinical neuropharmacology

authors： Müller T,Kolf K,Ander L,Woitalla D,Muhlack S

更新日期：2008-05-01 00:00:00

abstract：:Trazodone is a serotonin antagonist and reuptake inhibitor that is widely used for the treatment of depression and insomnia. Fatal overdose is rare and usually occurs when combined with other drugs or alcohol. Only a few lethal cases of pure trazodone overdose have been reported, all attributed to cardiotoxicity. We r...

journal_title：Clinical neuropharmacology

authors： Avila JD

更新日期：2017-09-01 00:00:00

abstract：:Levodopa (LD) is one of the most effective drugs for clinical symptoms in patients with Parkinson disease (PD). Most PD patients are advanced in age and may have trouble with LD absorption because aging influences drug absorption processes. Previous reports have indicated that ascorbic acid (AsA) can reduce LD dosage ...

journal_title：Clinical neuropharmacology

authors： Nagayama H,Hamamoto M,Ueda M,Nito C,Yamaguchi H,Katayama Y

更新日期：2004-11-01 00:00:00

abstract：:In a randomized double-blind study, 20 parkinsonian patients (suffering from the disease for 2-18 years), chronically treated with levodopa (500-750 mg/day for 0.5-12 years), received terguride (1 mg b.i.d.) or placebo for 4 weeks. Growth hormone (GH), prolactin (PRL), thyroid-stimulating hormone (TSH), and insulin-li...

journal_title：Clinical neuropharmacology

authors： Martignoni E,Horowski R,Liuzzi A,Costa A,Dallabonzana D,Cozzi R,Attanasio R,Rainer E,Nappi G

更新日期：1996-02-01 00:00:00

abstract：:To evaluate two different dosage regimens for albendazole (7.5 mg/kg twice a day or 5.0 mg/kg three times a day), a study was performed in 10 patients with a diagnosis of parenchymal brain cysticercosis. Each patient received both regimens sequentially according to a randomized, crossover design. Blood and urine sampl...

journal_title：Clinical neuropharmacology

authors： Sánchez M,Suástegui R,González-Esquivel D,Sotelo J,Jung H

更新日期：1993-02-01 00:00:00

abstract：:In a double-blind, 4 week study, 42 chronic schizophrenic inpatients receiving antipsychotic and antiparkinsonian (AP) drugs for greater than 3 months were either switched to placebo or maintained on biperiden. In the majority of the patients no clinically apparent discomfort was observed, and only two of 21 placebo p...

journal_title：Clinical neuropharmacology

authors： Wada Y,Koshino Y,Yamaguchi N

更新日期：1987-08-01 00:00:00

abstract：:To evaluate the efficacy and safety of gabapentin in the treatment of muscle cramps, we engaged an open-label trial with a group of 30 patients with frequent (> 5 cramps/week), stable, long-lasting cramps, associated with different diseases. Gabapentin was effective in reducing the frequency and severity of muscle cra...

journal_title：Clinical neuropharmacology

authors： Serrao M,Rossi P,Cardinali P,Valente G,Parisi L,Pierelli F

更新日期：2000-01-01 00:00:00

abstract：:Few studies have been published on the pharmacologic response to treatment of patients whose seizures begin after 40 years of age. The purpose of this study was to assess the impact of chronic pharmacotherapy on the seizure control of such patients. We retrospectively studied the seizure frequency recorded during a 12...

journal_title：Clinical neuropharmacology

authors： Hasegawa H,Kanner AM

更新日期：1995-02-01 00:00:00

abstract：OBJECTIVE:The purpose of this study is to investigate the safety and efficacy of aripiprazole in first-episode drug-naive patients with schizophrenia. METHODS:A total of 45 patients were enrolled in an open-label 12-week study. Dosing was determined by clinical judgment. The main efficacy measure was the Brief Psychia...

journal_title：Clinical neuropharmacology

authors： Takahashi H,Oshimo T,Ishigooka J

更新日期：2009-05-01 00:00:00

abstract：:Seven of 63 children (11%) treated with clobazam (CLB) for refractory epilepsy developed a severe behavior disorder. This disorder was characterized by aggressive agitation, self injurious behavior, insomnia, and incessant motor activity occurring between 10 and 55 days after initiation of drug therapy. The affected c...

journal_title：Clinical neuropharmacology

authors： Sheth RD,Goulden KJ,Ronen GM

更新日期：1994-08-01 00:00:00

abstract：:This study reports the antidepressant efficacy and the safety of amineptine (Survector 100) in a national multicenter open clinical trial (32 hospital centers). Three hundred twenty-four patients with depressive disorders, selected according to DSM-III Diagnostic Criteria and INSERM classification, were treated with a...

journal_title：Clinical neuropharmacology

authors： Kemali D

更新日期：1989-01-01 00:00:00

abstract：:The present study was carried out in order to verify whether, in benzodiazepine-medicated healthy volunteers, oxiracetam retained the properties already observed after administration in normal volunteers. In a cross-over study, 12 volunteers, medicated the night before with 5 mg diazepam, were i.v. treated with 1 g ox...

journal_title：Clinical neuropharmacology

authors： Giaquinto S,Nolfe G,Vitali S

更新日期：1986-01-01 00:00:00

abstract：:In this report, we present a patient whose positive symptoms did not improve despite being treated with clozapine monotherapy at a therapeutic dose for 4 months, and whose symptoms began to resolve after aripiprazole long-acting injection adjunction to clozapine. A 22-year-old man was diagnosed as having schizophrenia...

journal_title：Clinical neuropharmacology

authors： Balcioglu YH,Gokcay H,Yesilkaya UH

更新日期：2020-09-01 00:00:00